264 related articles for article (PubMed ID: 37307513)
1. The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition.
Gurbuxani S; Hochman MJ; DeZern AE; Shimamura A
Am Soc Clin Oncol Educ Book; 2023 Jun; 43():e390026. PubMed ID: 37307513
[TBL] [Abstract][Full Text] [Related]
2. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
[TBL] [Abstract][Full Text] [Related]
3. Molecular findings in myeloid neoplasms.
Tran TB; Siddon AJ
Int J Lab Hematol; 2023 Aug; 45(4):442-448. PubMed ID: 37345257
[TBL] [Abstract][Full Text] [Related]
4. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing.
Maierhofer A; Mehta N; Chisholm RA; Hutter S; Baer C; Nadarajah N; Pohlkamp C; Thompson ER; James PA; Kern W; Haferlach C; Meggendorfer M; Haferlach T; Blombery P
Blood Adv; 2023 Dec; 7(23):7346-7357. PubMed ID: 37874914
[TBL] [Abstract][Full Text] [Related]
5. [Genetic predisposition to myelodysplastic syndrome/leukemia].
Hirabayashi S
Rinsho Ketsueki; 2021; 62(8):1029-1037. PubMed ID: 34497189
[TBL] [Abstract][Full Text] [Related]
6. Pediatric Hematopathology in the Era of Advanced Molecular Diagnostics: What We Know and How We Can Apply the Updated Classifications.
Liu YC; Geyer JT
Pathobiology; 2024; 91(1):30-44. PubMed ID: 37311434
[TBL] [Abstract][Full Text] [Related]
7. Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.
Badar T; Chlon T
Curr Hematol Malig Rep; 2022 Oct; 17(5):113-120. PubMed ID: 35781188
[TBL] [Abstract][Full Text] [Related]
8. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
Hughes CFM; Gallipoli P; Agarwal R
Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
[TBL] [Abstract][Full Text] [Related]
9. Molecular alterations governing predisposition to myelodysplastic syndromes: Insights from Shwachman-Diamond syndrome.
Shimamura A
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101252. PubMed ID: 33762106
[TBL] [Abstract][Full Text] [Related]
10. Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene-Environment Interactions.
Cobaleda C; Godley LA; Nichols KE; Wlodarski MW; Sanchez-Garcia I
Cancer Discov; 2024 Mar; 14(3):396-405. PubMed ID: 38426560
[TBL] [Abstract][Full Text] [Related]
11. The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition.
Kanagal-Shamanna R
Curr Hematol Malig Rep; 2021 Aug; 16(4):336-344. PubMed ID: 34028637
[TBL] [Abstract][Full Text] [Related]
12. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
Abdulbaki R; Pullarkat ST
Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
[TBL] [Abstract][Full Text] [Related]
13. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
14. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
15. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
Stubbins RJ; Korotev S; Godley LA
Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.
Bacher U; Shumilov E; Flach J; Porret N; Joncourt R; Wiedemann G; Fiedler M; Novak U; Amstutz U; Pabst T
Blood Cancer J; 2018 Nov; 8(11):113. PubMed ID: 30420667
[TBL] [Abstract][Full Text] [Related]
17. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.
Li P; Brown S; Williams M; White T; Xie W; Cui W; Peker D; Lei L; Kunder CA; Wang HY; Murray SS; Vagher J; Kovacsovics T; Patel JL
Blood; 2022 Aug; 140(7):716-755. PubMed ID: 35671390
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.
Falini B; Martelli MP
Am J Hematol; 2023 Mar; 98(3):481-492. PubMed ID: 36606297
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope.
Elghetany MT; Patnaik MM; Khoury JD
Leuk Res; 2024 Feb; 137():107441. PubMed ID: 38301422
[TBL] [Abstract][Full Text] [Related]
20. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]